Camille De Craene, Associate Scientist • LMR Ghent – Nanobody Research Platform Discovery, BelgiumWe’re using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design, and improving the manufacturing and supply of medicines and vaccines to get them to patients in need faster.
AI is a catalyst to transform and rethink our business processes. We can transform the way we work to deliver better treatments, to support more patients, at higher quality and scale than ever before.
Dimitrije Jankovic
Head of Data & AI Strategy
Our Ambition
We’re all in on AI. We want to become the first biopharma company powered by AI at scale.
To achieve this, we’re investing where it counts; AI that enhances the work of our teams and allows them to focus on what matters most.
Zeinab Abou Khalil, Data Engineering Expert with Amandine Rusu and Richard Acosta Dianderas, Scrum Masters, Paris, FranceOur Commitment to Responsible AI
AI holds immense promise in our industry, and we’re excited by where it will take us. We recognize the importance of exploring this in a responsible manner to balance innovation with the right level of risk management.
To address these concerns, we’ve defined and implemented a robust Responsible AI governance and accountability framework to drive responsibility across the entire AI lifecycle, from design through use, and adopted a thoughtful risk-taking approach to bring it to life.
Responsible AI at Sanofi is guided by five key principles:
Accountable to Outcomes
L-R: Karel Verkoelen, Global Head of EBI Strategy & Governance, and Business Partner for Medical Affairs & Chief Medical Office (incl. Bioethics), Human Resources, Corporate Affairs and Corporate Strategy, Maria Moussadjy and Alexandre Blumenfeld, Senior Internal Auditor, FranceOur Partners
Innovation doesn’t happen in a vacuum or isolation. Through collaborations with leading companies in the AI space, we can bolster our internal capabilities and contribute to industry-wide breakthroughs.
